Opdivo Qvantig nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection Images

Generic Name: hyaluronidase/nivolumab

This medication has been identified as Opdivo Qvantig nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection. It is supplied by Bristol-Myers Squibb Company.

Opdivo Qvantig is used in the treatment of Head and Neck Cancer; Colorectal Cancer; Esophageal Carcinoma; Gastric Cancer; Hepatocellular Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Opdivo Qvantig nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Opdivo Qvantig

Generic Name: hyaluronidase/nivolumab
Strength: nivolumab 600 mg and hyaluronidase 10,000 units per 5 mL (120 mg/2,000 units per mL) injection
Availability: Prescription only
Drug Class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
CSA Schedule: Not a controlled drug
Labeler / Supplier: Bristol-Myers Squibb Company
National Drug Code (NDC): 00003-6120